23 completed, 5 terminated, 3 recruiting, 2 withdrawn. 18 Phase 2, 5 Phase 1, 5 Phase 3, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 12, Terminated 3, Withdrawn 2, Suspended 1 |
| Phase 1 | 5 | Completed 4, Suspended 1 |
| Phase 3 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
| Not applicable | 3 | Completed 3 |
Follow Basal Cell Nevus Syndrome: new trials by email Literature Review of Basal Cell Nevus Syndrome trials Research Report on Basal Cell Nevus Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib - Gorlin Syndrome | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 113 | 2024-03-17 | 2026-09-18 |
| Reproductive Options in Inherited Skin Diseases Ichthyosis, Palmoplantar Keratoses | Enrolling by invitation | Maastricht University Medical Center | 650 | 2024-01-01 | 2025-05-18 | |
| Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling Qualitative interview - Quality of Life, Ichthyosis | Recruiting | Maastricht University Medical Center | 25 | 2024-01-01 | 2025-05-18 | |
| Nevoid Basal Cell Carcinomas in Gorlin Syndrome Active surveillance - Basal Cell Carcinoma, Gorlin Syndrome | Completed | Oslo University Hospital | 7 | 2023-06-01 | 2026-10-09 | |
| Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study Vismodegib, Sonidegib - Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma | Recruiting | Maastricht University Medical Center | 80 | 2021-11-01 | 2025-04-04 | |
| CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome PTX-022, Vehicle comparator - BCCs in Gorlin Syndrome Patients | Phase 2 | Completed | Palvella Therapeutics, Inc. | 73 | 2021-05-06 | 2024-08-29 |
| Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor ASN-002 - Basal Cell Carcinoma, Basal Cell Nevus Syndrome | Phase 2 | Completed | Ascend Biopharmaceuticals Ltd | 21 | 2020-07-16 | 2024-04-10 |
| Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) Patidegib Topical Gel, 2% - Basal Cell Nevus Syndrome | Phase 3 | Terminated | Sol-Gel Technologies, Ltd. | 108 | 2020-06-03 | 2024-09-24 |
| A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Recurrent Basal Cell Carcinoma | Phase 2 | Terminated | Sol-Gel Technologies, Ltd. | 50 | 2019-12-20 | 2026-07-21 |
| Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome Vismodegib, Nivolumab, Ipilimumab - Basal Cell Nevus Syndrome | Phase 2 | Withdrawn | Columbia University | 2019-07-01 | 2019-12-18 | |
| Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Basal Cell Nevus Syndrome | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 174 | 2019-02-19 | 2024-07-03 |
| Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3 - Basal Cell Carcinoma, Basal Cell Nevus Syndrome | Phase 1 | Completed | Case Comprehensive Cancer Center | 37 | 2018-10-01 | 2024-10-17 |
| Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS) ASN-002 - Basal Cell Carcinoma in Basal Cell Nevus Syndrome | Phase 1 / Phase 2 | Suspended | Ascend Biopharmaceuticals Ltd | 24 | 2017-12-01 | 2023-02-06 |
| Familial Investigations of Childhood Cancer Predisposition Acute Leukemia, Adenomatous Polyposis | Recruiting | St. Jude Children's Research Hospital | 1500 | 2017-04-06 | 2026-06-17 | |
| Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas Patidegib, Vehicle gel - Basal Cell Carcinomas | Phase 2 | Completed | PellePharm, Inc. | 36 | 2016-11-11 | 2019-01-08 |
| Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients Patidegib, Vehicle gel - Basal Cell Nevus Syndrome | Phase 2 | Completed | PellePharm, Inc. | 17 | 2016-06-06 | 2020-07-23 |
| Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome Levulan, Red Light PDT, Blue Light PDT - Basal Cell Nevus Syndrome | Not applicable | Completed | Edward Maytin, MD, PhD | 3 | 2016-02-01 | 2020-07-30 |
| A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma ASN-002, 5-FU - Basal Cell Nevus Syndrome, Skin Neoplasm | Phase 1 / Phase 2 | Completed | Ascend Biopharmaceuticals Ltd | 16 | 2015-09-01 | 2018-06-06 |
| Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Buparlisib, Sonidegib - Carcinoma, Basal Cell, Recurrent Skin Cancer | Phase 2 | Terminated | Anne Chang | 10 | 2015-02-01 | 2019-01-29 |
| Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms levocarnitine, placebo, questionnaire administration - Musculoskeletal Complications | Not applicable | Completed | Stanford University | 12 | 2014-03-01 | 2017-08-04 |
Showing 20 of 35. Sign in to see all of them.
Carcinoma, Basal Cell (23) · Skin Neoplasms (4) · Tuberous Sclerosis (3) · Xeroderma Pigmentosum (3) · Albinism (2) · Birt-Hogg-Dube Syndrome (2) · Cutis Laxa (2) · Ectodermal Dysplasia (2) · Epidermolysis Bullosa (2) · Ichthyosis (2) · Keratoderma, Palmoplantar (2) · Neoplasms (2) · Adenomatous Polyposis Coli (1) · Adrenocortical Carcinoma (1)
Abnormalities, Multiple (35) · Bone Cysts (35) · Bone Diseases (35) · Bone Diseases, Developmental (35) · Congenital Abnormalities (35) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (35) · Cysts (35) · Genetic Diseases, Inborn (35) · Jaw Cysts (35) · Jaw Diseases (35) · Musculoskeletal Diseases (35) · Neoplasms by Histologic Type (35) · Neoplasms, Glandular and Epithelial (35) · Neoplastic Syndromes, Hereditary (35) · Odontogenic Cysts (35)
HhAntag691 (4) · sonidegib (4) · IPI-926 (3) · gusacitinib (3) · 1-phenyl-3,3-dimethyltriazene (2) · Aminolevulinic Acid (2) · Drug Evaluation (2) · Photochemotherapy (2) · tazarotene (2) · BMS-833923 (1) · Biopsy (1) · Blue Light (1) · Carboplatin (1) · Carnitine (1) · Comparative Genomic Hybridization (1)
UCSF Benioff Children's Hospital Oakland (6) · Novartis Pharmaceuticals (4) · Sol-Gel Technologies, Ltd. (4) · Ascend Biopharmaceuticals Ltd (3) · Maastricht University Medical Center (3) · PellePharm, Inc. (2) · Anne Chang (1) · Case Comprehensive Cancer Center (1) · Children's Oncology Group (1) · Columbia University (1) · Edward Maytin, MD, PhD (1) · Medical University of Graz (1) · Oslo University Hospital (1) · Palvella Therapeutics, Inc. (1) · QLT Inc. (1)
United States (20) · Netherlands (6) · United Kingdom (6) · Canada (5) · Germany (5) · Belgium (4) · Italy (4) · Spain (4) · Australia (3) · Austria (3) · France (3) · Denmark (2) · Switzerland (2) · Czechia (1) · Finland (1)
Ervin Epstein, MD (5) · Antoni Gostynski, MD, PhD (2) · David R. Bickers, MD (2) · Edward V. Maytin, MD, PhD (2) · Gregory Siller (2) · Allen E. Bale, MD (1) · Anna Bar (1) · Anne Lynn Chang (1) · Anne Lynn Chang, MD (1) · Clement Leong (1) · Clement Leong, Ph.D (1) · David Bickers, MD (1) · Ervin E Epstein, MD (1)
PMID 22670904, PMID 24441673, PMID 24623282, PMID 27838224, PMID 29175429
R01CA109584 (2), 2015 (1), 2023 (1), P30CA124435 (1), U10CA098543 (1), U10CA180886 (1), U19CA081888 (1)